ArticleJAMA internal medicine2020
Uptake of Infliximab Biosimilars Among the Medicare Population.
Article in JAMA internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease.Intestinal research · 2026Article
- Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry.Health services research · 2025Article
- Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease.Journal of clinical medicine · 2025Review
- Knowledge and Attitudes of Patients with Rheumatoid Diseases towards Biosimilars.Mediterranean journal of rheumatology · 2024Article
- Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2024Article
- TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System.Scientific reports · 2022Article
- Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients.World journal of clinical cases · 2022Review
- Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.JAMA network open · 2022Article
- Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.JAMA network open · 2021Article
- Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions.Crohn's & colitis 360 · 2021Article
- Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?Crohn's & colitis 360 · 2021Article
- Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.JAMA network open · 2021Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.